These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22489347)

  • 1. The circuitous path of PARP inhibitor development in epithelial ovarian cancer.
    Pothuri B
    Oncology (Williston Park); 2012 Feb; 26(2):144-6. PubMed ID: 22489347
    [No Abstract]   [Full Text] [Related]  

  • 2. The maze of PARP inhibitors in ovarian cancer.
    Nair A; Chen AP
    Oncology (Williston Park); 2012 Feb; 26(2):136-7, 141-2. PubMed ID: 22489346
    [No Abstract]   [Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
    Liu CH; Chang Y; Wang PH
    Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
    [No Abstract]   [Full Text] [Related]  

  • 4. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
    Scott CL; Swisher EM; Kaufmann SH
    J Clin Oncol; 2015 Apr; 33(12):1397-406. PubMed ID: 25779564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
    Zorn KK
    Oncology (Williston Park); 2012 Feb; 26(2):128-36. PubMed ID: 22489345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors in Epithelial Ovarian Cancer.
    Taylor KN; Eskander RN
    Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
    Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
    BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular targeted therapies for epithelial ovarian cancer].
    Itamochi H; Kigawa J
    Nihon Rinsho; 2012 Jun; 70 Suppl 4():622-7. PubMed ID: 23156321
    [No Abstract]   [Full Text] [Related]  

  • 10. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
    Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
    Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib for the treatment of epithelial ovarian cancer.
    McLachlan J; Banerjee S
    Expert Opin Pharmacother; 2016; 17(7):995-1003. PubMed ID: 26967466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
    Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    Gadducci A; Guerrieri ME
    Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
    Lorusso D; Fontanella C; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
    Expert Opin Drug Saf; 2017 Jun; 16(6):687-696. PubMed ID: 28471247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.